Use of hormonal contraceptives and risk of HIV-1 transmission

The Lancet Infectious Diseases

Volumn 12, Issue 7, 2012, Pages 509-510

  Jones, Heidi E ^a   Schooling, C Mary ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ENANTATE; ORAL CONTRACEPTIVE AGENT;

CONTRACEPTION; DISEASE TRANSMISSION; FAMILY PLANNING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; INFECTION RISK; LETTER; PRIORITY JOURNAL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NOTE;

CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE;

EID: 84862728910     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70110-X     Document Type: Letter

References (5)

1. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012, 12:19-26.
2. Morrison CN, Nanda K Hormonal contraception and HIV: an unanswered question. Lancet Infect Dis 2012, 12:2-3.
3. Bouman A, Heineman MJ, Faas MM Sex hormones and the immune response in humans. Hum Reprod Update 2005, 11:411-423.
4. Mishell DR, Kharma KM, Thorneycroft IH, Nakamura RM Estrogenic activity in women receiving an injectable progestogen for contraception. Am J Obstet Gynecol 1972, 113:372-376.
5. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey SG Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008, 27:1133-1163.